IPO
넥스아이
What the company does
NexEye is a new drug development company that out-licenses candidate drugs, mainly at the preclinical to Phase 2 stage, to global pharmaceutical companies. Its main target is immunotherapy-refractory cancer treatments.
- Market
- KOSDAQ
- Price range
- ₩10,500 – ₩13,000
- Offer price
- ₩10,500
- Subscription
- Nov 3 – Nov 4
- Payment date
- Nov 6, 2026
- Listing
- Not set yet
- Shares offered
- 5,000,000
- Raising
- ₩52.5B
Lead managers: Korea Investment & Securities
Filings
- 투자설명서Oct 22, 2026Open on DART ↗
- [기재정정]증권신고서(지분증권)Oct 16, 2026Open on DART ↗
- 증권신고서(지분증권)Sep 28, 2026Open on DART ↗
How a Korean IPO works: institutions bid first (the demand forecast), which sets the final offer price; then individuals subscribe for two days through the lead managers' brokerage accounts; shares start trading on the listing date.
Dates and prices can change until the final terms are filed. Not financial advice. · Updated Oct 29, 2026 · IPO calendar